100s of titles, one news app for just $10 a month.
Dive Deeper:
Centre will probe use of psychedelic drugs in fight against mental health conditions
Centre will investigate the potential for psychedelic drugs to be used to tackle various chronic mental health conditions
Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
Psychedelics policy action took center stage this week. 
ACHV: First Quarter 2022 Results
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year
AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease.…
One subscription that gives you access to news from hundreds of sites
How to treat adult ADHD: A psychologist explains medication and more
Adult ADHD is challenging, but there are ways to treat it. Here's what you need to know
Long Covid sufferers at far greater risk of blood clots, study says
Symptoms can last months after initial infection and include fatigue, shortness of breath and brain fog
Get all your news in one place
Latest Technology news:
Apple iPhone Supply Chain Proving 'Surprisingly Resilient,' Analyst Says
Despite fears that Covid outbreaks in China would severely impact Apple's operations, the consumer electronics giant is faring better than…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
This VR gas mask can actually take your breath away
From blowing out birthday candles to suffocating from smoke inhalation, this VR accessory takes you just a step below the…
7 years later, the RPG with the most memorable world still holds up
It's the 7th anniversary of arguably the best action RPG of the past decade — a game that flourishes thanks…
Tech & Science Daily: Nasa on their Moon mission, behind the scenes
NASA’s Volatiles Investigating Polar Exploration Rover, or VIPER
No privacy reform commitments from major parties
The Coalition is uncommitted to privacy reform and Labor remains silent despite broad support from independents and minor parties, according…
From analysis to good news, read the world’s best news in one place
A Top Tesla Shareholder Proposes "Undervalued" Stock Buyback Strategy
Tesla's third-largest individual shareholder KoGuan Leo encourages the company to use free cash flow to buy back Tesla shares at…
Tesla's Service Manuals Now Free Of Charge, Grab Them While You Can
Tesla's "Service and Repair Information" subscription package, which includes service, parts and body repair manuals, used to cost $3,187 a…

Can LSD Treat Anxiety? MindMed's New Topline Data Show Promise, Here's The Research

By Fermin Orgambide

MindMed (NASDAQ: MNMD) researchers shared topline clinical results for a Phase 2 LSD clinical study at the recent Psych Symposium, which was co-sponsored by University Hospital Basel (UHB).
Prof. Matthias Liechti and Dr. Friederike Holze, MindMed collaborators at UHB, commented that initial results for the trial showed LSD’s significant, rapid and durable effects when mitigating symptoms of anxiety and depression.
The placebo-controlled study enrolled 46 people who received 200 micrograms of LSD - considered a large dose. Taking the State-Trait Anxiety Inventory (STAI) global score, a questionnaire used to assess the severity of anxiety symptoms, it was found that 65% of participants reduced their anxiety levels by at least 30%. The measurement was taken 16 weeks after dosing and greatly exceeded anxiety reduction in patients who took a placebo, of whom only 9% reached the 30% reduction in symptoms.

“These results represent the highest quality research ever conducted with LSD in anxiety disorders and provide contemporary confirmation of the preliminary findings of the anxiolytic and antidepressant effects of LSD in over 500 patients to date,” said Dr. Miri Halperin Wernli, executive president of MindMed. 
The novelty of this study is not only the reduction in anxiety levels but also that there was no therapy involved. That is, the goal of the trial was to measure what role could LSD play in reducing anxiety symptoms by itself, not in psychedelics-enhanced therapy.
Liechti, one of the primary investigators of the study, explained that “while psychedelics including LSD have shown beneficial effects on reducing anxiety, there has still been a need for a deeper understanding of the mechanisms and the long-lasting effects by which psychedelics exert their therapeutic effects. Thus, we designed a robust, randomized, placebo-controlled clinical trial with a long follow-up period to extend the promising findings of previously conducted smaller, open-label trials.”

Photo: Courtesy of Pretty Drugthings on Unsplash.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Centre will probe use of psychedelic drugs in fight against mental health conditions
Centre will investigate the potential for psychedelic drugs to be used to tackle various chronic mental health conditions
Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
Psychedelics policy action took center stage this week. 
ACHV: First Quarter 2022 Results
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year
AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease.…
One subscription that gives you access to news from hundreds of sites
How to treat adult ADHD: A psychologist explains medication and more
Adult ADHD is challenging, but there are ways to treat it. Here's what you need to know
Long Covid sufferers at far greater risk of blood clots, study says
Symptoms can last months after initial infection and include fatigue, shortness of breath and brain fog
Get all your news in one place